Friday, January 4, 2013 Thursday, January 3, 2013- Will More Data Make the Difference for Merck?at Motley Fool (Thu, Jan 3)
- Digital Health Companies Must Make Themselves Indispensable To Established Stakeholdersat Forbes (Thu, Jan 3)
- Cohen’s SAC Tops Most Profitable List Amid Insider Probesat Bloomberg (Thu, Jan 3)
- The Biggest (Potential) Turnaround Story in Pharmaat Motley Fool (Thu, Jan 3)
- Cramer: Should You Date the Darlings of the Dow in 2013?at CNBC (Thu, Jan 3)
- Bayer-Teva Animal Deal Clears FTCat Motley Fool (Thu, Jan 3)
- Pfizer Licenses Spinal Muscular Atrophy Program From Repligenat Motley Fool (Thu, Jan 3)
- Can Antares' Products Power Your Portfolio in 2013?at Motley Fool (Thu, Jan 3)
- Wall Street's Riskiest Tradeat Forbes (Thu, Jan 3)
- Halozyme Therapeutics's Key Deal With Pfizer Is Significantat Seeking Alpha (Thu, Jan 3)
- Are Short-Sellers Onto Something at Peregrine?at Motley Fool (Thu, Jan 3)
- Labrys Bioscience, founded by Corey Goodman, snags Pfizer migraine drug, $31 millionat bizjournals.com (Thu, Jan 3)
- [video] Morningstar's Top Fund Managersat CNBC (Thu, Jan 3)
- What Will Be the Top Dog in 2013?Zacks (Thu, Jan 3)
- What You Need to Know About Big Pharmaat Motley Fool (Thu, Jan 3)
- Chevron Announces New Reserves and 3 Dow Movers Seeing Actionat Wall St. Cheat Sheet (Thu, Jan 3)
- Ex-SAC Manager Martoma Pleads Not Guilty to Insider Tradingat Bloomberg (Thu, Jan 3)
- Repligen forms partnership on spinal muscle drugAP (Thu, Jan 3)
- Schizo-Well Fargo? Bank Has Two Market Gurus – Two Very Different 2013 PredictionsYCharts (Thu, Jan 3)
- 2 Risks That Could Crush MannKind in 2013at Motley Fool (Thu, Jan 3)
- Inside The Pricing Of A $300,000-A-Year Drugat Forbes (Thu, Jan 3)
- 2012 job cuts lowest since 1997, says Challenger, Grayat bizjournals.com (Thu, Jan 3)
- S&P 500 Index Gains the Most Since 2009 -- Fiscal Cliff Likely to Be AvoidedMarketwired (Thu, Jan 3)
Add PFE News to My Yahoo!   | |
|
1.35%